Lisanti Capital Growth LLC Makes New Investment in GeneDx Holdings Corp. (NASDAQ:WGS)

Lisanti Capital Growth LLC bought a new position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 36,615 shares of the company's stock, valued at approximately $1,554,000. Lisanti Capital Growth LLC owned approximately 0.14% of GeneDx as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in shares of GeneDx in the 2nd quarter worth approximately $34,000. nVerses Capital LLC acquired a new position in shares of GeneDx in the second quarter valued at approximately $50,000. CWM LLC bought a new position in shares of GeneDx during the third quarter worth about $89,000. SG Americas Securities LLC acquired a new stake in GeneDx in the 3rd quarter valued at $198,000. Finally, Palumbo Wealth Management LLC acquired a new position in GeneDx during the third quarter worth $287,000. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Stock Down 5.7 %

Shares of NASDAQ:WGS traded down $4.41 on Monday, reaching $73.39. The company had a trading volume of 865,123 shares, compared to its average volume of 446,434. GeneDx Holdings Corp. has a 52-week low of $1.16 and a 52-week high of $89.11. The firm has a market capitalization of $2.02 billion, a PE ratio of -24.89 and a beta of 2.11. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The firm's 50 day simple moving average is $51.68 and its 200-day simple moving average is $35.86.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. During the same period last year, the company posted ($0.82) EPS. GeneDx's quarterly revenue was up 44.3% compared to the same quarter last year. As a group, analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Insider Transactions at GeneDx

In related news, CFO Kevin Feeley sold 895 shares of the business's stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $33.33, for a total value of $29,830.35. Following the transaction, the chief financial officer now owns 39,910 shares in the company, valued at $1,330,200.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Katherine Stueland sold 2,154 shares of the stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $66.60, for a total value of $143,456.40. Following the completion of the sale, the chief executive officer now owns 105,426 shares in the company, valued at approximately $7,021,371.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Feeley sold 895 shares of the business's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $33.33, for a total transaction of $29,830.35. Following the transaction, the chief financial officer now directly owns 39,910 shares in the company, valued at approximately $1,330,200.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 962,848 shares of company stock worth $68,298,009. 27.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have commented on the company. BTIG Research upped their price objective on GeneDx from $35.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, July 31st. The Goldman Sachs Group boosted their price objective on GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a research report on Wednesday, October 30th. Craig Hallum lifted their price objective on GeneDx from $70.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Wells Fargo & Company raised their target price on GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 30th. Finally, TD Cowen upped their price objective on shares of GeneDx from $46.00 to $50.00 and gave the stock a "buy" rating in a report on Wednesday, July 31st. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $59.33.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.